A 68930 and dihydrexidine inhibit locomotor activity and d-amphetamine-induced hyperactivity in rats: a role of inhibitory dopamine D(1/5) receptors in the prefrontal cortex?
D000818:Animals; D001552:Benzazepines / Q000494:pharmacology; D002839:Chromans / Q000494:pharmacology*; D003913:Dextroamphetamine / Q000494:pharmacology; D015259:Dopamine Agents / Q000494:pharmacology; D018491:Dopamine Agonists / Q000494:pharmacology*; D018492:Dopamine Antagonists / Q000494:pharmacology; D015870:Gene Expression / Q000187:drug effects; D006948:Hyperkinesis / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D009433:Neural Inhibition / Q000187:drug effects / Q000502:physiology; D010617:Phenanthridines / Q000494:pharmacology*; D017397:Prefrontal Cortex / Q000187:drug effects* / Q000502:physiology; D016760:Proto-Oncogene Proteins c-fos / Q000235:genetics; D020891:Raclopride / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017447:Receptors, Dopamine D1 / Q000502:physiology; D019956:Stereotypic Movement Disorder / Q000139:chemically induced / Q000188:drug therapy / Q000503:physiopathology
D001552:Benzazepines; D002839:Chromans; D015259:Dopamine Agents; D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D010617:Phenanthridines; D016760:Proto-Oncogene Proteins c-fos; D017447:Receptors, Dopamine D1; C061532:dihydrexidine; D020891:Raclopride; C065380:A 68930; D003913:Dextroamphetamine